Open Access
Journal of Personalized Medicine, volume 12, issue 6, pages 895
VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
Publication type: Journal Article
Publication date: 2022-05-29
Journal:
Journal of Personalized Medicine
Quartile SCImago
Q2
Quartile WOS
—
Impact factor: —
ISSN: 20754426
Medicine (miscellaneous)
Abstract
Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58) and iB20 (class VH3-53/66), are capable of neutralizing the recently emerged Omicron (BA.1) variant. Both nAbs were found to bind the Omicron RBD with a nanomolar affinity, yet they displayed contrasting functional features. When tested against Omicron, the neutralizing activity of iB14 was reduced 50-fold, whereas iB20 displayed a surprising increase in activity. Thus, iB20 is a unique representative of the VH3-53/66-class of nAbs in terms of breadth of neutralization, which establishes it as a candidate for COVID-19 therapy and prophylactics.
Top-30
Citations by journals
|
1
2
|
|
|
Vaccines
2 publications, 50%
|
|
|
Frontiers in Immunology
1 publication, 25%
|
|
|
Russian Chemical Reviews
1 publication, 25%
|
|
|
1
2
|
Citations by publishers
|
1
2
|
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
2 publications, 50%
|
|
|
Frontiers Media S.A.
1 publication, 25%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 25%
|
|
|
1
2
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2024],"ids":[0],"codes":[0],"imageUrls":[""],"datasets":[{"label":"Citations number","data":[4],"backgroundColor":["#3B82F6"],"percentage":["100"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Vaccines","Frontiers in Immunology","Russian Chemical Reviews"],"ids":[24868,1699,23802],"codes":[0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/9Mus3KG1Tkd7Bwaurt8H3RwWh0CxRlGoO6ng9UK1_medium.webp"],"datasets":[{"label":"","data":[2,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6"],"percentage":[50,25,25],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Multidisciplinary Digital Publishing Institute (MDPI)","Frontiers Media S.A.","Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii"],"ids":[202,208,9422],"codes":[0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/9Mus3KG1Tkd7Bwaurt8H3RwWh0CxRlGoO6ng9UK1_medium.webp"],"datasets":[{"label":"","data":[2,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6"],"percentage":[50,25,25],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":false}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartiles":{"type":"bar","data":{"show":true,"labels":[2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[0],"percentage":["0"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[0],"percentage":["0"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[0],"percentage":["0"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[4],"percentage":["100"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[0],"percentage":["0"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by SCImago per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"yearsCitationsQuartilesWs":{"type":"bar","data":{"show":true,"labels":[2024],"ids":[],"codes":[],"imageUrls":[],"datasets":[{"label":"Q4","backgroundColor":"rgb(221,90,78)","data":[0],"percentage":["0"]},{"label":"Q3","backgroundColor":"rgb(251, 163,83)","data":[0],"percentage":["0"]},{"label":"Q2","backgroundColor":"rgb(232, 213, 89)","data":[0],"percentage":["0"]},{"label":"Q1","backgroundColor":"rgb(164, 207, 99)","data":[4],"percentage":["100"]},{"label":"Quartile not defined","backgroundColor":"#E5E7EB","data":[0],"percentage":["0"]}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"},"stacked":true}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations quartiles by WoS per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Kulemzin S. V. et al. VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages // Journal of Personalized Medicine. 2022. Vol. 12. No. 6. p. 895.
GOST all authors (up to 50)
Copy
Kulemzin S. V., Sergeeva M. V., Baranov K., Gorchakov A. A., Guselnikov S. V., Belovezhets T. N., Volkova O. Yu., Najakshin A. M., Chikaev N. A., Danilenko D., Taranin A. VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages // Journal of Personalized Medicine. 2022. Vol. 12. No. 6. p. 895.
Cite this
RIS
Copy
TY - JOUR
DO - 10.3390/jpm12060895
UR - https://doi.org/10.3390/jpm12060895
TI - VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages
T2 - Journal of Personalized Medicine
AU - Kulemzin, Sergey V
AU - Sergeeva, Maria V
AU - Guselnikov, Sergey V
AU - Belovezhets, Tatyana N
AU - Volkova, Olga Yu
AU - Najakshin, Alexander M.
AU - Chikaev, Nikolai A
AU - Baranov, Konstantin
AU - Gorchakov, Andrey A
AU - Danilenko, Daria
AU - Taranin, Alexander
PY - 2022
DA - 2022/05/29 00:00:00
PB - Multidisciplinary Digital Publishing Institute (MDPI)
SP - 895
IS - 6
VL - 12
SN - 2075-4426
ER -
Cite this
BibTex
Copy
@article{2022_Kulemzin,
author = {Sergey V Kulemzin and Maria V Sergeeva and Sergey V Guselnikov and Tatyana N Belovezhets and Olga Yu Volkova and Alexander M. Najakshin and Nikolai A Chikaev and Konstantin Baranov and Andrey A Gorchakov and Daria Danilenko and Alexander Taranin},
title = {VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages},
journal = {Journal of Personalized Medicine},
year = {2022},
volume = {12},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
month = {may},
url = {https://doi.org/10.3390/jpm12060895},
number = {6},
pages = {895},
doi = {10.3390/jpm12060895}
}
Cite this
MLA
Copy
Kulemzin, Sergey V., et al. “VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages.” Journal of Personalized Medicine, vol. 12, no. 6, May. 2022, p. 895. https://doi.org/10.3390/jpm12060895.